{"success":true,"limit_reached":false,"status_code":200,"error_message":null,"csv":null,"symbol":"IMVT","asset_type":"Common Stock","name":"ImmunovantÂ Inc","description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.","central_index_key":"1764013","exchange":"NASDAQ","currency":"USD","country":"USA","sector":"LIFE SCIENCES","Industry":"BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)","address":"320 WEST 37TH STREET, NEW YORK, NY, US","fiscal_year_end":"March","latest_quarter":"2024-09-30","market_capitalization":"3468513000","ebitda":"-352164992","pe_ratio":"None","pe_growth_ratio":"None","book_value":"3.064","dividend_per_share":"None","dividend_yield":"None","earnings_per_share":"-2.2","revenue_per_share_ttm":"0","profit_margin":"0","operating_margin_ttm":"0","return_on_assets_ttm":"-0.545","return_on_equity_ttm":"-0.922","revenue_ttm":"0","gross_profit_ttm":"0","diluted_eps_ttm":"-2.2","quarterly_earnings_growth_yoy":"0","quarterly_revenue_growth_yoy":"0","analyst_target_price":"50.25","trailing_pe":"-","forward_pe":"-","price_to_sales_ratio_ttm":"-","price_to_book_ratio":"7.67","ev_to_revenue":"-","ev_to_ebitda":"-14.12","beta":"42.44","fifty_two_week_high":"42.44","fifty_two_week_low":"23.07","fifty_day_moving_average":"27.51","two_hundred_day_moving_average":"28.73","shares_outstanding":"146785000","dividend_date":"None","ex_dividend_date":"None"}